Sign in

    Leonildo Delgado

    Senior Equity Analyst at Baader Helvea

    Leonildo Delgado is a Senior Equity Analyst at Baader Helvea specializing in healthcare and biotechnology, with coverage of companies such as Atai Life Sciences, Addex Therapeutics, HBM Healthcare, Newron Pharmaceuticals, and DEMIRE. Over his career, he has generated research with deep sector insight, though recent performance metrics show challenges, including a 0% published success rate and an average return of -77.32%, placing him in the lower quartile among analysts tracked publicly. Delgado holds a Ph.D. and actively participates in earnings calls, providing detailed financial analysis and forecasts; his professional experience centers around European equity research, with no confirmed prior firms before Baader Helvea. His credentials include advanced academic qualifications, but there is no public record of FINRA registration or securities licenses.

    Leonildo Delgado's questions to Addex Therapeutics (ADXN) leadership

    Leonildo Delgado's questions to Addex Therapeutics (ADXN) leadership • Q1 2024

    Question

    Leonildo Delgado of Baader Helvea inquired about the potential financial upside for Addex from the Neurosterix transaction beyond the initial CHF 5 million payment, particularly regarding its 20% equity stake, and asked for a timeline on Janssen's decision for the ADX71149 epilepsy program.

    Answer

    Executive Timothy Dyer explained that Addex's 20% equity in Neurosterix was valued at approximately $20 million post-transaction, with significant upside potential tied to the M4 PAM program's progress, citing recent multi-billion dollar deals in the space. Regarding the epilepsy program, Dyer stated that after the Phase II study missed its primary endpoint, Addex expects the full data set from Janssen in H2 2024, likely Q3, after which next steps will be determined, with a potential outcome being the return of the molecule to Addex.

    Ask Fintool Equity Research AI

    Leonildo Delgado's questions to Addex Therapeutics (ADXN) leadership • Q1 2024

    Question

    Leonildo Delgado of Baader Helvea inquired about the potential financial upside from the Neurosterix deal beyond the initial CHF 5 million payment, specifically regarding the 20% equity stake, and also asked for the timeline on Janssen's decision for the ADX71149 epilepsy program.

    Answer

    Timothy Dyer (executive) detailed that the upside from the Neurosterix deal is contained within Addex's 20% equity stake, valued at approximately $20 million post-transaction, with significant potential as Neurosterix advances its M4 PAM program. Regarding the ADX71149 epilepsy program, Dyer explained that following disappointing top-line results, a full data analysis is underway with partner Janssen, with next steps to be determined in H2 2024, possibly resulting in the program's return to Addex.

    Ask Fintool Equity Research AI

    Leonildo Delgado's questions to Addex Therapeutics (ADXN) leadership • Q3 2023

    Question

    Leonildo Delgado of Baader Helvea inquired about the immediate implications for Addex in 2024 if the Phase II epilepsy study for ADX71149 yields positive results in Q2 2024.

    Answer

    Executive Timothy Dyer explained that since their partner, Janssen, is operationally and financially responsible for the study, Addex has limited control and visibility. However, he stated that a positive outcome would likely lead Janssen to advance the program into a pivotal study, though Janssen's specific future development plans are not yet confirmed.

    Ask Fintool Equity Research AI

    Leonildo Delgado's questions to Addex Therapeutics (ADXN) leadership • Q1 2023

    Question

    Leonildo Delgado of Baader Helvea questioned the company's cash runway guidance into 2024, asking if it implied a halt in R&D activities. He also asked if the positive epilepsy study news has led to concrete partnering offers.

    Answer

    Executive Timothy Dyer clarified that the cash runway extends into 2024 due to a significant reduction in R&D expenses after closing out the Dipraglurant Phase III study, combined with recent financing of $4.5 million. He affirmed there are no plans for restructuring. Regarding partnerships, he stated that while multiple discussions are active across the portfolio, he could not provide specific details on term sheets, but highlighted the high value and interest in programs like mGlu7, M4 PAM, and chronic cough.

    Ask Fintool Equity Research AI